secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-09-18T20:06:23+00:00
Accession:  0001140361-26-037114
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics annual meeting: directors re-elected, say-on-pay approved
----------------------------------------------------------------------------

- Annual meeting held Sept 17, 2026; 9,973,325 shares present (61.28% of 16,274,026 outstanding).
- All five director nominees elected: Kavuru, Davis, Kohli, Kottayil, Neugeboren, each with ~6.0M votes for.
- Say-on-pay approved: 5,740,999 for vs 222,775 against (93% support excluding broker non-votes).
- KPMG LLP ratified as auditor for FY2027: 9,878,292 for, 63,381 against.
- Shareholders favor 1-year frequency for say-on-pay (5,772,652 votes); board adopts annual vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126037114/0001140361-26-037114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126037114/ef20082416_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-037114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer